Combining adebrelimab with chemotherapy for lung cancer treatment
A Randomized Phase II Study of Adebrelimab in Combination with Chemotherapy with or Without Bevacizumab Neoadjuvant Therapy for Resectable Non-Squamous Non-Small Cell Lung Cancer
This study is testing if adding adebrelimab to chemotherapy helps patients with early-stage lung cancer feel better and have better treatment outcomes before surgery.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | The First Affiliated Hospital of Guangzhou Medical University Academic / other |
| Drugs / interventions | chemotherapy, adebrelimab, bevacizumab |
| Locations | 1 site (Guangzhou) |
| Trial ID | NCT06775275 on ClinicalTrials.gov |
What this trial studies
This Phase II clinical trial evaluates the safety and efficacy of adebrelimab in combination with chemotherapy, with or without bevacizumab, for patients with resectable Stage II-IIIB non-small cell lung carcinoma (NSCLC). The study is multicenter and randomized, focusing on treatment-naive patients who have not undergone prior surgery or chemotherapy. Participants will receive neoadjuvant therapy followed by surgical intervention, and the study will also explore biomarkers related to treatment efficacy.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-65 with resectable non-squamous non-small cell lung cancer and good pulmonary function.
Not a fit: Patients with small cell lung cancer, squamous cell carcinoma, or those who have previously received certain immunotherapies or anti-angiogenic drugs may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment approach could improve outcomes for patients with resectable lung cancer by enhancing the effectiveness of neoadjuvant therapy.
How similar studies have performed: While this approach is being explored in this specific context, similar combinations of immunotherapy and chemotherapy have shown promise in other studies, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Resectable NSQ NSCLC * Age 18-65 years * male or female * ECOG 0-1 * Subjects have not received surgery, chemotherapy, radiotherapy and biological treatment of treatment-naive non-squamous non-small cell lung cancer * Subjects must have adequate pulmonary function for the intended pneumonectomy; Exclusion Criteria: * SCLC or SQ NSCLC * previously used anti-PD1, anti-PDL1, anti-CTLA4 antibodies, etc. * patients who have previously used anti-angiogenic drugs; * allergic to any component of the study drug or chemotherapy drugs * patients with any severe and or uncontrolled disease
Where this trial is running
Guangzhou
- Department of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University — Guangzhou, China (Recruiting)
Study contacts
- Principal investigator: Jianxing He — The First Affiliated Hospital of Guangzhou Medical University
- Study coordinator: Jianxing He
- Email: jianxing.he@gmail.com
- Phone: +86-20-83062807
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.